Menu
Recruiting NCT07316296

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

Phase III Interventional Parkinson's Disease (PD) Freezing of Gait Freezing of Gait Symptoms in Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Atomoxetine, Placebo.
Who it may be relevant to
Registry conditions: Parkinson's Disease (PD), Freezing of Gait, Freezing of Gait Symptoms in Parkinson Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is: Does atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait? Researchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease. Participants will: Visit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life

Interventions

  • Drug Atomoxetine
    Single dose, 40mg atomoxetine, capsule
  • Drug Placebo
    Single dose, placebo (microcrystalline cellulose), capsule

Primary outcome measures

  • The percentage of time frozen in the dopaminergic OFF-state [Time frame: Baseline, visit 2 (one week after baseline) and visit 3 (one week after visit 2).]
Secondary outcome measures (2)
  • The percentage of time frozen in the dopaminergic ON-state [Time frame: Baseline, visit 2 (one week after baseline) and visit 3 (one week after visit 2).]
  • The brain network integration-segregation coefficient [Time frame: Visit 2 (one week after baseline) and visit 3 (one week after visit 2).]

Eligibility criteria

Inclusion criteria

  • Aged 18 years or older;
  • Diagnosis of idiopathic PD according to MDS Diagnostic Criteria;
  • Stabilised on optimal dopaminergic PD treatment for a minimum of four weeks prior to the baseline visit (Visit 1) and for the duration of the trial;
  • Presence of FOG symptoms on a daily basis;
  • Ability to walk for 10-meters unaided in the dopaminergic ON-state;
  • Ability to provide written informed consent in accordance with ICH-GCP and local regulations;
  • Willing and able to undergo all clinical trial assessments.

Exclusion criteria

  • Current and/or previous (within 3 months) participation in a clinical trial;
  • Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker);
  • Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments);
  • Severe cognitive impairment hampering the ability to comply with the study protocol;
  • Active psychosis that would impact the ability to comply with the study protocol;
  • Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc > 500ms Bazett-formula) and channelopathies that in the opinion of the study PI would significantly compromise participant safety;
  • Severe cerebrovascular disorders: cerebral aneurysm or recent/significant stroke;
  • Hepatic or renal insufficiency that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;
  • Narrow angle glaucoma;
  • (History of) pheochromocytoma;
  • Use of noradrenergic agents;
  • Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine);
  • Use of high dose salbutamol (or other beta2 agonists) that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;
  • Pregnancy and/or breastfeeding;
  • Known hypersensitivity to atomoxetine.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Triple blind
Primary purpose
Treatment

Study locations

Netherlands · 1 center
  • Radboudumc — Nijmegen

Identifiers

NCT: NCT07316296 · R0007688A

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗